KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Accumulated Depreciation & Amortization (2016 - 2025)

Neogenomics filings provide 14 years of Accumulated Depreciation & Amortization readings, the most recent being $209.1 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 10.04% to $209.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $209.1 million, a 10.04% increase, with the full-year FY2025 number at $209.1 million, up 10.04% from a year prior.
  • Accumulated Depreciation & Amortization hit $209.1 million in Q4 2025 for Neogenomics, up from $190.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $209.1 million in Q4 2025 to a low of $110.0 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $158.2 million (2023), compared with a mean of $159.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 324.46% in 2021 and later grew 10.04% in 2025.
  • Neogenomics' Accumulated Depreciation & Amortization stood at $110.0 million in 2021, then grew by 19.99% to $131.9 million in 2022, then rose by 19.92% to $158.2 million in 2023, then grew by 20.09% to $190.0 million in 2024, then increased by 10.04% to $209.1 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $209.1 million (Q4 2025), $190.0 million (Q4 2024), and $158.2 million (Q4 2023) per Business Quant data.